文献速递核素与放射性配体治疗放射性药物与辐射防护

延长[177Lu]Lu-PSMA-617治疗对肾脏吸收剂量及CKD-EPI值的影响:治疗可安全持续多久

Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-10

本研究纳入110例接受≥4周期[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,计算累积肾脏吸收剂量(cRD)并评估其对肾功能的影响。结果显示cRD与CKD-EPI值无显著相关(p>.05),第4至8周期后CKD-EPI较治疗前无显著差异(p>.05);cRD达23 Gy的患者治疗前后CKD-EPI差异有统计学意义(p<.05)。作者认为个体化剂量学方法或可支持延长治疗周期且肾毒性可控。

要点

  • 110例接受≥4周期[177Lu]Lu-PSMA-617治疗者中,cRD与CKD-EPI值无显著相关(p>.05)。
  • 第4至8周期后CKD-EPI与治疗前无显著差异(p>.05)。
  • cRD达23 Gy者治疗前后CKD-EPI差异有统计学意义(p<.05)。

核心结论

  • 尽管治疗相关eGFR下降,个体化剂量学方法或可支持延长[177Lu]Lu-PSMA-617治疗周期且肾毒性可控。
  • 鉴于患者间显著变异,建立通用吸收剂量-反应关系仍有挑战。
  • 作者认为需前瞻性多中心研究以完善毒性阈值并推进个体化治疗策略。

研究设计与样本

  • 研究纳入110例接受≥4周期[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者。
  • 给药后4、24、96小时行全身静态及腹部SPECT-CT显像。
  • 治疗前行动态肾显像及生化检查评估肾功能。
  • 每个治疗周期前及治疗后第6周采用CKD-EPI公式计算eGFR。

主要发现

  • Pearson相关分析显示cRD与CKD-EPI值无显著关系(p>.05)。
  • 治疗前CKD-EPI与第4、5、6、7、8周期后测值间无显著差异(p>.05)。
  • cRD达23 Gy的患者中,治疗前后CKD-EPI值差异有统计学意义(p<.05)。
  • cRD超过28 Gy的13例患者中,5例治疗后CKD-EPI维持在90 mL/min/1.73 m2以上。

局限性

  • 作者指出患者间存在显著变异,建立通用吸收剂量-反应关系仍有挑战。
  • 作者认为需前瞻性多中心研究以完善毒性阈值并推进个体化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to evaluate the personalized dosimetric approach by calculating the cumulative renal absorbed dose (cRD) and assessing its impact on renal functions in patients diagnosed with metastatic castration-resistant prostate cancer who underwent four or more cycles of [177Lu] Lu-PSMA - 617 therapy. METHODS: The study included 110 patients who received ≥ 4 cycles of [177Lu] Lu-PSMA - 617 therapy. Whole-body static and abdominal SPECT-CT imaging was performed at 4, 24, and 96 h post-administration. Kidney function was assessed using dynamic renal scintigraphy and biochemical tests conducted prior to treatment. Estimated glomerular filtration rate (eGFR) levels were calculated using the CKD-EPI formula before each treatment cycle and at the 6th week post-treatment. RESULTS: Pearson correlation analysis reveal no significant relationship between cRD and CKD-EPI values (p >.05). No significant differences were observed between pre-treatment CKD-EPI levels and those measured after the 4th, 5th, 6th, 7th, and 8th cycles (p >.05). Among patients reaching a cRD of 23 Gy, a statistically significant difference was observed between pre- and post-treatment CKD-EPI values (p <.05). Of the 13 patients exceeding cRD of 28 Gy, five maintained CKD-EPI levels above 90 mL/min/1.73 m2 post-treatment. CONCLUSION: Despite treatment-related declines in eGFR levels, our findings indicate that a personalized dosimetric approach may enable extended cycles of [177Lu] Lu-PSMA-617 therapy with manageable nephrotoxicity. Considering the significant inter-patient variability, establishing universal absorbed dose-response relationships remains challenging. Prospective multicenter studies are crucial to refining toxicity thresholds and advancing tailored treatment strategies to optimize safety and efficacy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Topal E, Kovan B, İribas A, et al. Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued? Eur J Nucl Med Mol Imaging. 2025. PMID: 40063298. doi:10.1007/s00259-025-07125-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。